Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Interest Expenses (2016 - 2025)

Guided Therapeutics' Interest Expenses history spans 15 years, with the latest figure at $129000.0 for Q3 2025.

  • For Q3 2025, Interest Expenses rose 19.44% year-over-year to $129000.0; the TTM value through Sep 2025 reached $567000.0, up 77.74%, while the annual FY2024 figure was $381000.0, 37.05% up from the prior year.
  • Interest Expenses for Q3 2025 was $129000.0 at Guided Therapeutics, down from $157000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $594000.0 in Q3 2021 and bottomed at $64000.0 in Q1 2024.
  • The 5-year median for Interest Expenses is $108000.0 (2024), against an average of $148631.6.
  • The largest annual shift saw Interest Expenses surged 339.39% in 2021 before it crashed 73.91% in 2022.
  • A 5-year view of Interest Expenses shows it stood at $100000.0 in 2021, then decreased by 30.0% to $70000.0 in 2022, then rose by 2.86% to $72000.0 in 2023, then surged by 86.11% to $134000.0 in 2024, then dropped by 3.73% to $129000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Interest Expenses are $129000.0 (Q3 2025), $157000.0 (Q2 2025), and $147000.0 (Q1 2025).